Mutations in the epidermal growth factor receptor (EGFR): Retro-and prospective observations in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib

被引：0
|
作者：
Nederlof, R
Boerrigter, L
Van 't Veer, L
Baas, P
van Zandwijk, N
机构：
[1] Netherlands Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S111 / S111
页数：1
相关论文
共 50 条
  • [1] Epidermal growth factor receptor (EGFR) mutation testingin non-small cell lung cancer (NSCLC) patients (pts).
    Sequist, L. V.
    Joshi, V. A.
    Jänne, P. A.
    Fidias, P.
    Muzikansky, A.
    Meyerson, M.
    Haber, D. A.
    Kucherlapati, R.
    Johnson, B. E.
    Lynch, T. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 408S - 408S
  • [2] Mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC).
    Sonobe, M
    Katakura, H
    Adachi, T
    Wada, H
    Tanaka, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 637S - 637S
  • [3] Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib.
    Riely, GJ
    Miller, VA
    Pao, W
    Zakowski, M
    Ladanyi, M
    Heelan, RT
    Kris, MG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 641S - 641S
  • [4] Epidermal growth factor receptor mutations in Greek gefitinib-treated non-small-cell lung cancer (NSCLC) patients
    Voutsina, A
    Pallis, AG
    Souglakos, J
    Koutsopoulos, A
    Kalykaki, A
    Trypaki, M
    Mavroudis, D
    Georgoulias, V
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
  • [5] A prospective phase II study of gefitinib in non-small cell cancer patients with epidermal growth factor receptor gene (EGFR) mutations
    Sugio, K.
    Uramoto, H.
    Oyama, T.
    Onizuka, T.
    Ichiki, Y.
    Yasuda, M.
    Sugaya, M.
    Nozoe, T.
    Takenoyama, M.
    Hanagiri, T.
    Yasumoto, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Previously documented mutations in the epidermal growth factor receptor (EGFR) gene in a non-small cell lung cancer (NSCLC) population treated with gefitinib are not associated with response.
    Bebb, D. G.
    Pugh, T.
    Sutcliffe, M.
    Barclay, L.
    Fee, J.
    O'Connor, R.
    Vielkind, J.
    Murray, N.
    Laskin, J. J.
    Marra, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 404S - 404S
  • [7] Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations
    Wu, Jenn-Yu
    Shih, Jin-Yuan
    Chen, Kuan-Yu
    Yang, Chih-Hsin
    Yu, Chong-Jen
    Yang, Pan-Chyr
    [J]. MEDICINE, 2011, 90 (03) : 159 - 167
  • [8] Impact of epidermal growth factor receptor (EGFR) mutations on responsiveness of non-small cell lung cancer (NSCLC) to tyrosine kinase inhibitors (TKIS): Prospective observations
    van Zandwijk, Nico
    Mathy, Alexandre
    de Jong, Daphne
    Baas, Paul
    Burgers, Sjaak
    Nederlof, Petra
    [J]. EJC SUPPLEMENTS, 2006, 4 (06): : 14 - 15
  • [9] Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
    Zhou, Yongchun
    Yang, Yanlong
    Yang, Chenggang
    Chen, Yunlan
    Yang, Changshao
    Du, Yaxi
    Zhao, Guangqiang
    Guo, Yinjin
    Ye, Lianhua
    Huang, Yunchao
    [J]. ONCOTARGET, 2017, 8 (09) : 15023 - 15033
  • [10] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    [J]. LUNG CANCER, 2005, 49 : S112 - S113
12345